In 2018, Johnson & Johnson embarked on a mission to transform the way blood clots are studied. Their aim was to determine how various clot characteristics such as size, composition, and density could impact patient outcomes, as well as how two of the company’s medical devices fared in clot removal. They conducted a study that involved enrolling 1,000 stroke patients at 36 clinical trial sites around the world to analyze actual blood clots that had been removed from stroke patients.
Johnson & Johnson’s Excellent Registry is the largest acute ischemic stroke registry globally. It collects patient data, imaging, and clot information on a per-pass basis, with independent evaluators reviewing the data. This initiative highlights the company’s dedication to innovation in advancing stroke care. Given the alarming statistics that every 40 seconds someone in the United States has a stroke and every 3.5 minutes someone dies from one, Johnson & Johnson’s commitment to improving stroke care is crucial.
The study aimed to understand how different factors such as size, composition and density of blood clots can affect patient outcomes and also assessed the performance of two of Johnson & Johnson’s medical devices in removing blood clots from stroke patients. The findings from this study will help healthcare professionals make more informed decisions about treatment options for patients with blood clots and improve overall outcomes for those affected by strokes
